CBRS enters the week after earnings with a sharp disconnect at its core: the Street remains overwhelmingly bullish with targets near $292 on average, yet the stock has shed 13% over the past month to $172.62, CEO Andrew Feldman sold roughly $33.8 million of stock last week, and short interest has climbed 32% in seven days.
The insider angle is the most concrete signal in this setup. Feldman executed six open-market sales on August 21, offloading around 169,514 shares across a price range of $197 to $202 — none filed under a 10b5-1 plan, meaning these were discretionary trades, not pre-scheduled. That raises the signal value relative to a routine selling program. Net insider activity across the 90-day window stands at roughly -$47.3 million, with a net reduction of about 238,000 shares. A separate activist holder, Lior Susan, also trimmed their stake below the 5% disclosure threshold — their most recent 13D/A filing on August 18 shows a reduction from 5.2% to 4.3%. As always with 13D/G disclosures, these stakes reflect the position as last reported, and holders who drop below 5% may not file again.
Short positioning tells a clearly more aggressive story than it did a month ago. Estimated short interest climbed 32% week-on-week to around 13.5 million shares, recovering from a dip to 9.2 million in late August and putting it back near its July highs of 13.5 million. The ORTEX short score has edged up to 67.9, its highest reading of the past two weeks. What makes the lending market more interesting than the raw short count is how sharply availability has swung: it dropped to near zero through much of August — touching 0.17% on August 13, meaning the borrow pool was essentially exhausted — before loosening materially this week to around 19%. That sudden increase in availability, combined with a cost to borrow that has fallen from a peak of 2.67% in early August to just 1.08% now, suggests a wave of new shares entered the lending pool. Cheaper borrow and easier access typically remove friction for new short positions to be built. The borrow market has gone from near-impossible to merely tight in the space of a fortnight.
Options positioning is broadly neutral rather than strongly directional. The put/call ratio runs at 0.97, modestly above its 20-day average of 0.93 but only 0.26 standard deviations from the mean — nowhere near the defensive extreme. The 52-week PCR high of 1.33 came on August 17, the same period when availability was near zero and the stock was under heavy borrow pressure; that period of elevated put demand has since faded. Overall, options traders are not sounding an alarm in either direction.
The Street remains firmly in the bull camp despite the stock's recent weakness. Analyst moves following the August 12 earnings print were broadly constructive: UBS raised its target to $330, Morgan Stanley lifted to $279, and Wedbush moved to $290 — all maintaining positive ratings. Citi trimmed slightly from $340 to $320 but kept its Buy. Rosenblatt and Needham both reiterated $300 targets on August 19. The mean price target across the coverage universe is approximately $292, implying around 69% upside from the current price. The bull case centres on Cerebras' wafer-scale processor lead in fast inference and the CS-4's performance advantage, while bears point to significant customer concentration and dependence on third-party supply chains. FMR LLC remains the largest disclosed institutional holder at roughly 12% of shares. The institutional register is notably dense with high-conviction names — Atreides, Coatue, Altimeter, and Benchmark all appear — though several of these positions were first disclosed at IPO and reflect pre-float stakes rather than recent open-market conviction.
The next earnings date is September 22. After the August 12 print, the stock fell 1.6% on the day and 8.1% over the following five days — a pattern worth holding in mind given the CEO's decision to sell at $197–$202 ahead of a stock now trading at $172. The question heading into that September print is whether the gap between a consensus target near $292 and a stock at $172 tightens on execution, or whether the combination of insider selling, rebuilding short interest, and loosening borrow conditions signals that informed participants are positioned for further pressure.
See the live data behind this article on ORTEX.
Open CBRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
